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Abstract
Background: Our paper addresses three major public health issues: cholesterol, statins and policies to prevent
cardiovascular disease.
Discussion: Total cholesterol levels in whole populations have fallen substantially in the USA, UK and most other
developed countries. This has greatly contributed to decreases in cardiovascular disease deaths. The evidence
identifying diet as the major contributor to these historical falls in cholesterol is powerful and consistent. Large falls
occurred before statins were introduced. Additional substantial falls occurred before statins were widely used.
Now, up to 14% adults in Western populations currently receive statins for primary prevention. Furthermore,
because diet is now only slowly improving, the statin contribution currently appears proportionately larger.
Summary: In conclusion, diet change explains most of the historical falls in cholesterol. Until very recently, the
contribution from statins has been surprisingly modest. Furthermore, many middle income countries may have
neither the resources nor the infrastructure for mass statin therapy.
Further substantial falls in cholesterol are therefore unlikely to be obtained simply by increased use of statins or
dietary advice to individuals if unsupported by the wider environment. This further emphasises the need for more
effective structural policies. Regulatory and fiscal interventions could easily eradicate industrial transfats, halve the
intake of dietary saturated fat, and subsidise healthier fats.
Background
In recent decades, mean population total cholesterol
levels have fallen by as much as 1.0 mmol/l (40 mg/dl)
in most developed countries. Understanding why is cru-
cial for planning future health strategies to prevent car-
diovascular disease (CVD). Cholesterol has major public
health importance as a powerful cause of atherosclerosis
and thrombosis, hence coronary heart disease and
ischemic stroke. Every 1% fall in mean population total
cholesterol levels decreases CVD mortality by approxi-
mately 2.5% [1]. Thus, recent population cholesterol
falls explain up to 25% of the concomitant decreases in
cardiovascular mortality in the USA, Canada and else-
where [2]. However, cholesterol levels in every country
remain substantially above the optimal level of approxi-
mately 4.5 mmol/l [1-3].
Total blood cholesterol consists of sub-fractions.
Approximately two thirds being low density lipoprotein
(LDL, the main villain for CVD), some 30% comes from
high density lipoprotein, (HDL, which is protective
against CVD) and the remainder comes from very low
density lipoproteins (triglycerides) [1]. Although trend
d a t ao nL D La n dH D La r el i m i t e do u t s i d et h eU S A ,
happily, changes in total cholesterol levels are highly
correlated with LDL [1].
We now address a key question: Why have total cho-
lesterol and LDL levels fallen in most developed coun-
tries? Is it mainly statins, or diet or other factors?
Discussion
First licensed in the late 1980s, statin prescribing first
increased slowly, then exponentially from the late 1990s
to now reach approximately 14% of US and UK adults
[3]. It is therefore perhaps useful to distinguish three
separate time-periods, the “pre-statin”, “early statin” and
“current statin” eras.
For the “pre-statin” era, the substantial population falls
in cholesterol must obviously be attributed to other fac-
tors, principally diet. Between 1960 and 1994, US
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(18 mg/dl). Equally large falls were also seen internation-
ally, including Finland and New Zealand (Table 1).
In the “early statin era” (the late 1990s), individuals
clearly benefited from medication. Initially, the emphasis
was on secondary prevention for selected patients with
recognised disease. Yet, even after publication of Air
Force/Texas Coronary Atherosclerosis Prevention Study
in 1998, statins were initially prescribed to only a small
fraction of eligible adults (consistently less than 4%). Popu-
lation effects would clearly have been limited. Yet substan-
tial total cholesterol falls of 0.14-0.8 mmol/l (5-30 mg/dl)
were observed in diverse populations (Table 1).
In the “current statin era” prescribing rates are now
substantial, ranging from 9% in Sweden [4] to 12% in the
UK and 14% in the USA [3]. Furthermore, because recent
absolute cholesterol falls have been modest, statins may
now explain perhaps 45% of the falls in the UK between
2003 and 2006, and almost all (88% - 98%) of the recent
fall in the US population between 1999 and 2006 (Table 1).
Future strategy options for population-wide cholesterol
reduction
Further cholesterol reduction will be essential to reduce
the future burden of CVD. The key challenge is to iden-
tify the most effective and cost-effective strategy.
Table 1 Cholesterol trends in whole populations in the “Pre-statin”, “Early statin” and “Current statin” eras*
Population Survey
Years
Data Source
(approximate
sample size)
Number of
Adults on
statins
Adults on long
term statins
(Primary and
secondary
prevention)
Mean total cholesterol
reduction in whole
population
Men (women)
mmol/l
Estimated
contribution from
statins†
(%)
First
author
&
reference
“The Pre-Statin Era”
USA 1960-1994 NHANES
(44,980)
0 0 -0.41 (-0.52 ) 0% Carroll 2005
[14]
New
Zealand
1982-1993 ARCOS (3,800) 0 0 -0.45 (-0.66 ) 0% Capewell
2000 [15]
Finland 1982-1997 FinRisk
(13,000)
0 0 -0.64 (-0.66 ) 0% Laatikainen
2005 [16]
Scotland 1985-1994 MONICA
(5,900)
0 0 -0.10 (-0.40 ) 0% Capewell
1999 [17]
“The Early Statin Era”
England 1981-2000 BRHS & HSE
(17,500)
280,000 < 1% -0.14 (-0.07) 5% Unal 2004
[18]
Ireland 1985-2000 Kilkenny &
SLAN surveys
(7,900)
60,000 2% -0.35 (-0.22) 5% Bennett
2006 [19]
Italy 1980-2000 RIFLE and
OEC surveys
(62,000)
900,000 3% -0.33 (-0.37 ) 6% Palmieri
2009 [20]
Sweden 1986-2002 MONICA &
INTERGENE
(8,800)
280,000 4% -0.55 (-0.68) 6% Bjorck 2009
[21]
Iceland 1981-2006 IHA
population
studies
(17,700)
4,000 2% -0.80 (-0.95) Aspelund
2010 [22]
“The Current Statin Era”
UK 2003-2006 HSE (15,500) 4.4 million 11% -0.20 (- 0.20) 41% Mindell
2009 [23]
USA 1994-2002 NHANES
(14,530)
18 million 9% -0.078 (-0.08) 88% Carroll 2005
[14]
USA 1999-2006 NHANES
(18,050)
28 million 14% -0.106 (-0.11) 95% Ford 2009
[3]
TABLE FOOTNOTE
*Statin eras defined pragmatically as: “Pre-statin era": before 1997; “Early-statin era": 1997 - 1999; and “Current statin era": since 2000, using the most recent year
for which data are available.
†Methodology for calculating statin contribution is detailed in Additional File 1, Appendix B.
Statin uptake in Sweden increased substantially between 2002 and 2009 (Eriksson M. et. al. J Intern Med. 2011;269:219-231).
Abbreviations: ARCOS = Auckland Region Coronary Or Stroke; BRHS = British Regional Heart Study; HSE = Health Survey for England; MONICA = Monitoring
Trends and Determinants on Cardiovascular Diseases; NHANES = National Health and Nutrition Examination Survey; OEC = Osservatorio Epidemiologico
Cardiovascolare; RIFLE = Risk Factors and Life Expectancy; SLAN = Survey of Lifestyle, Attitudes, and Nutrition.
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Identify and treat more individuals with statins?
Statins powerfully lower cholesterol in individuals, yet
simple logic suggests that statin benefits across an entire
population may be much diluted. Doubling the current
level of statin prescribing would increase costs but
achieve surprisingly modest reductions in cardiovascular
mortality [[5] and Additional File 1, Appendix A].
Firstly because of the law of diminishing returns:
expanding the criteria for statin prescribing would cap-
ture individuals with progressively lower absolute event
rates. Secondly, because control of hypercholesterolae-
mia (defined as the proportion of all hypercholesterolae-
mic individuals subsequently achieving blood levels
below 5 mmol/l (200 mg/dl) remains frustratingly poor,
typically ranging from 17% to just 31% [3]. This med-
iocre population impact probably reflects progressive
attrition down Tugwell’s “staircase”, whereby effective-
ness decreases at each step in the complex clinical path-
way from initial awareness, access, coverage, screening,
targeting, diagnosis, and compliance through to patient
adherence [5]. Even after successful testing and advice,
only a proportion of patients repeatedly fill a statin pre-
scription [6]. Statin compliance (adherence) is proble-
matic, approximately half of patients actually take their
statin medication every day [6]. And long-term persis-
tence is also poor: 12 months after commencing therapy,
barely 50% continue on statins [5]. Moreover, statin dos-
ing is often suboptimal, with a correspondingly weaker
cholesterol reduction [5,6]. Thus statin effectiveness in
ordinary clinical practice will clearly be decreased, per-
haps reducing cholesterol by approximately 1 mmol/l
(40 mg/dl), rather than the 2 mmol/l (80 mg/dl) efficacy
achieved in selected patients in controlled trials [7].
Diet and Cholesterol
The extensive evidence identifying dietary fats as the
major contributor to cholesterol levels ranges from ran-
domised controlled trials to population-wide natural
experiments. “Bad” saturated fats and trans fats substan-
tially increase LDL and total cholesterol levels. Conver-
sely, “good” polyunsaturates and monounsaturates raise
HDL and decrease LDL and total blood cholesterol
levels. Thus replacement is beneficial in the laboratory,
and in the community [6]. For instance, in Poland in
1990, communist subsidies for animal fats disappeared
and a free market provided relatively cheap vegetable
oils, fruit and vegetables. The polyunsaturate/saturate
ratio improved substantially, and coronary death rates
fell by 24% within five years. Corresponding trends were
reported in East Germany, Hungary and the Czech
Republic [7].
Less powerful factors modestly reducing LDL and
total cholesterol levels should also be briefly considered.
Most are nutritional. Plant-based diets (fresh fruit,
vegetables and wholegrain cereals) and Mediterranean
type diets significantly decrease total cholesterol and
LDL [8]. Furthermore, CVD mortality is approximately
25% lower in individuals routinely consuming a vegetar-
ian or “prudent diet” (lots of fruit and vegetables, nuts,
cereals and fish, little meat or dairy) and is correspond-
ingly higher with a “Western diet” (more meat and
dairy) [8]. Changes in diet and other lifestyle behaviors
are powerfully influenced by socio-economic factors.
Affluent and educated groups generally display healthier
dietary patterns, these being facilitated by greater dispo-
sable income. Statin use is likewise generally greater in
more affluent groups [9-12].
Modest cholesterol reductions might also be attributed to
hormone replacement therapy. However, after the
adverse publicity surrounding the Women’s Health Initia-
tive results, prescribing almost halved and, furthermore,
any cholesterol lowering benefits would be mainly confined
to peri-menopausal women. Sustained exercise may
decrease total cholesterol in individuals by approximately
0.10 mmol/l (4 mg/dl). Optimistically assuming a 5%
increase in US or UK population prevalence of moderate
physical activity since 1980 might therefore mean, at best, a
0.005 mmol/l (0.2 mg/dl) reduction in total cholesterol [2].
Conversely, increasing obesity trends will adverse
affect cholesterol levels. However, the effect is surpris-
ingly small - every unit increase in body mass index
m a yi n c r e a s en o n - H D Lc h o l e s t e r o lb yo n l ya b o u t00 4 5
mmol/l (2 mg/dl). Furthermore, equally substantial cho-
lesterol falls have actually been observed in all sections
of the population, whether obese, overweight or normal
weight [13].
Future Strategy Option 2: PUBLIC HEALTH POLICIES TO
PROMOTE HEALTHIER DIETS?
Large cholesterol decreases occurred before the wide-
spread use of statins. The evidence consistently identi-
fies dietary fat changes as the main contributor.
However, recent diet improvements in the US and UK
have been frustratingly slow. Effective diet policy inter-
ventions do exist - legislative, fiscal and social levers
have worked elsewhere [4,8-10]. These levers could be
used in the US, UK and elsewhere to eliminate indus-
trial transfats, halve the intake of dietary saturated fat
and increase the consumption of polyunsaturates and
monounsaturates.
Summary
Cholesterol reduction represents a major public health
priority in the campaign to prevent cardiovascular dis-
ease. Statins are generally viewed as the only solution;
but this ignores both the historical facts and the scienti-
fic evidence.
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fallen substantially in the USA, UK and most other
developed countries. Large falls actually occurred before
statins were introduced [14-17]. Further substantial falls
occurred before statins were widely used [18-23]. More-
over, the evidence identifying diet as the major contri-
butor to these historical falls in cholesterol is powerful
and consistent.
Now, however, things are less simple. Up to 14%
adults in Western populations currently receive statins
for primary prevention. And because diet is now only
slowly improving, the statin contribution currently
appears proportionately larger. Yet, many middle
income and low income countries may have neither
the resources nor the infrastructure for mass statin
therapy. Further substantial falls in cholesterol are
unlikely to be obtained simply by increased use of sta-
tins, nor by further dietary advice to individuals with-
out additional support from the wider socio-economic
environment.
This highlights the need to consider more effective
structural policies. The evidence underpinning regula-
tory and fiscal interventions is impressive. Such popula-
tion-wide policies could easily eradicate industrial
transfats, halve the intake of dietary saturated fat, and
subsidise healthier fats.
Additional material
Additional file 1: Appendix A. The potential mortality benefits if statins
were prescribed to a larger proportion of hypercholesterolaemic adults.
Appendix B. Methodology: estimating the statin contribution to the
overall reduction in population cholesterol levels.
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